Müllerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 44, 2010, Pages 18874-18879

  Wei, Xiaolong ^a   Dombkowski, David ^b   Meirelles, Katia ^a   Pieretti Vanmarcke, Rafael ^a   Szotek, Paul P ^a   Chang, Henry L ^a   Preffer, Frederic I ^b   Mueller, Peter R ^a   Teixeira, Jose ^a   MacLaughlin, David T ^a   Donaho, Patricia K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Anthrapyrazolone; Chemotherapy resistance; Stem progenitor cell enriched populations

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CD24 ANTIGEN; CELL MARKER; CISPLATIN; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; MEMBRANE ANTIGEN; MUELLERIAN INHIBITING FACTOR; PACLITAXEL; ANTHRA(1,9 CD)PYRAZOL 6(2H) ONE; ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONE; ANTHRACENE DERIVATIVE; ANTINEOPLASTIC AGENT; CD24 PROTEIN, HUMAN; CD44 PROTEIN, HUMAN; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STEM CELL; CELL INVASION; CELL ISOLATION; CELL MIGRATION; CELL POPULATION; CELL SELECTION; CONFERENCE PAPER; CONTROLLED STUDY; DILUTION; DRUG SENSITIVITY; FEMALE; FIMBRIA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

ANTHRACENES; ANTI-MULLERIAN HORMONE; ANTIGENS, CD24; ANTIGENS, CD44; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649908639     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1012667107     Document Type: Article

References (62)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988. (Pubitemid 36418143)
2. Bapat SA, Mali AM, Koppikar CB, Kurrey NK (2005) Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65:3025-3029.
3. Li C, et al. (2007) Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037.
4. Szotek PP, et al. (2006) Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 103:11154-11159.
5. Szotek PP, et al. (2008) Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics. Proc Natl Acad Sci USA 105:12469-12473.
6. Knoblich JA (2008) Mechanisms of asymmetric stem cell division. Cell 132:583-597.
7. Morrison SJ, Spradling AC (2008) Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell 132:598-611.
8. Gupta PB, Chaffer CL, Weinberg RA (2009) Cancer stem cells: Mirage or reality? Nat Med 15:1010-1012.
9. Baba T, et al. (2009) Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 28:209-218.
10. Cannistra SA, et al. (2003) Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol 21(suppl 10):129s-132s.
11. Jemal A, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
12. Alvarez AA, Krigman HR, Whitaker RS, Dodge RK, Rodriguez GC (1999) The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 5:587-591.
13. Quirk JT, Natarajan N, Mettlin CJ (2005) Age-specific ovarian cancer incidence rate patterns in the United States. Gynecol Oncol 99:248-250. (Pubitemid 41354614)
14. Ho SM (2003) Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 1:73.
15. Körner M, Burckhardt E, Mazzucchelli L (2005) Different proportions of aneusomic cells in ovarian inclusion cysts associated with serous borderline tumours and serous high-grade carcinomas support different pathogenetic pathways. J Pathol 207:20-26.
16. Landen CN, Jr, Birrer MJ, Sood AK (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26:995-1005.
17. Shih IeM, Kurman RJ (2005) Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 11:7273-7279.
18. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC (1996) Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183:1797-1806.
19. Kondo T, Setoguchi T, Taga T (2004) Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 101:781-786.
20. Masiakos PT, et al. (1999) Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res 5:3488-3499.
21. Pieretti-Vanmarcke R, et al. (2006) Mullerian inhibiting substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci USA 103:17426-17431.
22. Stephen AE, et al. (2002) Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res 8:2640-2646.
23. Renlund N, et al. (2008) c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction. Endocrinology 149:108-115.
24. Teixeira J, et al. (1996) Developmental expression of a candidate müllerian inhibiting substance type II receptor. Endocrinology 137:160-165.
25. Fuller AF, Jr, Guy S, Budzik GP, Donahoe PK (1982) Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line. J Clin Endocrinol Metab 54:1051-1055.
26. Haraguchi N, et al. (2006) Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24:506-513.
27. Moserle L, Ghisi M, Amadori A, Indraccolo S (2010) Side population and cancer stem cells: therapeutic implications. Cancer Lett 288:1-9.
28. Wulf GG, et al. (2001) A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98:1166-1173.
29. Connolly DC, et al. (2003) Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 63:1389-1397.
30. Rodina AV, et al. (2008) Localization of Mullerian inhibiting substance receptors in various human cancer cell lines. Biochemistry (Mosc) 73:797-805.
31. Callahan MJ, et al. (2007) Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 25: 3985-3990.
32. Crum CP, et al. (2007) Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 5:35-44.
33. Crum CP, et al. (2007) The distal fallopian tube: A new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 19:3-9.
34. Alvero AB, et al. (2009) Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 8:158-166.
35. Choi D, et al. (2009) Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 15:2258-2264.
36. Dalerba P, et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104:10158-10163.
37. Hong SP, Wen J, Bang S, Park S, Song SY (2009) CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 125:2323-2331.
38. Horst D, Kriegl L, Engel J, Kirchner T, Jung A (2009) Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 27:844-850.
39. Marhaba R, et al. (2008) CD44 and EpCAM: Cancer-initiating cell markers. Curr Mol Med 8:784-804.
40. Munz M, Baeuerle PA, Gires O (2009) The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 69:5627-5629.
41. Takaishi S, et al. (2009) Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27:1006-1020.
42. Curley MD, et al. (2009) CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 27:2875-2883.
43. Mizrak D, Brittan M, Alison MR (2008) CD133: Molecule of the moment. J Pathol 214: 3-9.
44. Shmelkov SV, St Clair R, Lyden D, Rafii S (2005) AC133/CD133/Prominin-1. Int J Biochem Cell Biol 37:715-719.
45. Lim SC (2005) CD24 and human carcinoma: Tumor biological aspects. Biomed Pharmacother 59(suppl 2):S351-S354.
46. Sagiv E, Arber N (2008) The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: From research to therapy. Expert Rev Gastroenterol Hepatol 2:125-133.
47. Zhang S, et al. (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68:4311-4320.
48. Gao MQ, Choi YP, Kang S, Youn JH, Cho NH (2010) CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 29:2672-2680.
49. Yeung TM, Gandhi SC, Wilding JL, Muschel R, Bodmer WF (2010) Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci USA 107:3722-3727.
50. Geiger B, Ayalon O (1992) Cadherins. Annu Rev Cell Biol 8:307-332.
51. Mareel M, Vleminckx K, Vermeulen S, Bracke M, Van Roy F (1992) E-cadherin expression: A counterbalance for cancer cell invasion. Bull Cancer 79:347-355.
52. Dave B, Chang J (2009) Treatment resistance in stem cells and breast cancer. J Mammary Gland Biol Neoplasia 14:79-82.
53. Corney DC, et al. (2010) Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 16:1119-1128.
54. Corney DC, Nikitin AY (2008) MicroRNA and ovarian cancer. Histol Histopathol 23: 1161-1169.
55. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC (1997) Increased platinum- DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 57:850-856.
56. Schilder RJ, et al. (1990) Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 45:416-422.
57. Fogh J, Wright WC, Loveless JD (1977) Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 58:209-214.
58. Hirschmann-Jax C, et al. (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101:14228-14233.
59. Bénard J, et al. (1985) Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 45:4970-4979.
60. Lorenzo HK, et al. (2002) New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity. J Chromatogr B Analyt Technol Biomed Life Sci 766:89-98.
61. Ragin RC, Donahoe PK, Kenneally MK, Ahmad MF, MacLaughlin DT (1992) Human müllerian inhibiting substance: Enhanced purification imparts biochemical stability and restores antiproliferative effects. Protein Expr Purif 3:236-245.
62. Preffer F, Dombkowski D (2009) Advances in complex multiparameter flow cytometry technology: Applications in stem cell research. Cytometry B Clin Cytom 76:295-314.